287954-99-8

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 

Downstream Products

• 1262399-75-6 4-(4-bromo-phenyl)-1-methanesulfonyl-1,2,3,6-tetrahydro-pyridine 
• 622386-94-1 4-(4-bromophenyl)-1-(methylsulfonyl)piperidine 

Relevant academic research and scientific papers

GPR119 Agonists

GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.

TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.

Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.